Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 34

Results For "EPS"

576 News Found

Pfizer acquires Seagen for US$ 43 billion to battle cancer
News | March 14, 2023

Pfizer acquires Seagen for US$ 43 billion to battle cancer

Proposed combination enhances Pfizer’s position as a leading company in oncology


Eugia Pharma receives USFDA approval for Lenalidomide Capsules
Drug Approval | March 09, 2023

Eugia Pharma receives USFDA approval for Lenalidomide Capsules

The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone


Sonowal inaugurates SCO’s first international conference on traditional medicine
News | March 04, 2023

Sonowal inaugurates SCO’s first international conference on traditional medicine

The WHO - Global Center for Traditional Medicine will help member countries in taking enabling steps in their countries for strengthen education and practices of traditional mdicine


Sanofi reaffirms commitment to rare diseases in India
News | February 28, 2023

Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India


Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets
Digitisation | February 27, 2023

Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets

New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator


Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores
News | February 16, 2023

Panacea Biotec posts Q3 FY2023 net profit at Rs.19.37 crores

The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.


Balaxi Pharmaceuticals revenue up 40.3%
News | February 02, 2023

Balaxi Pharmaceuticals revenue up 40.3%

During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore


Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
News | January 24, 2023

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility


Dabur India expects low to mid-single digit revenue growth for Q3 FY23
News | January 07, 2023

Dabur India expects low to mid-single digit revenue growth for Q3 FY23

International Business is expected to post double-digit revenue growth during the quarter in constant currency.